NewAmsterdam Pharma Company N.V. $NAMS Shares Acquired by Wellington Management Group LLP

Key Points

• Wellington Management Group LLP increased its stake in NewAmsterdam Pharma by 53.0%, acquiring 1,226,852 additional shares to bring its total ownership to about 3.23%, valued at approximately $72.5 million.
• COO Douglas F. Kling sold 100,000 shares of NewAmsterdam Pharma for nearly $1.93 million, significantly reducing his ownership by 69.44%, while Director James N. Topper increased his position by purchasing 8,584 shares.
• The latest earnings report showed NewAmsterdam Pharma reported ($0.15) earnings per share, exceeding the consensus estimate by $0.37, with revenue of $19.15 million for the quarter.

Wellington Management Group LLP lifted its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 53.0% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 3,541,975 shares of the company's stock after purchasing an additional 1,226,852 shares during the quarter. Wellington Management Group LLP owned about 3.23% of NewAmsterdam Pharma worth $72,504,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of NewAmsterdam Pharma by 19.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock worth $80,000 after purchasing an additional 596 shares during the period. GF Fund Management CO. LTD. purchased a new position in NewAmsterdam Pharma in the 4th quarter worth approximately $50,000. Geode Capital Management LLC boosted its holdings in NewAmsterdam Pharma by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 88,544 shares of the company's stock worth $2,276,000 after acquiring an additional 2,222 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in NewAmsterdam Pharma by 12.5% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 22,028 shares of the company's stock worth $451,000 after acquiring an additional 2,439 shares during the period. Finally, HB Wealth Management LLC boosted its holdings in NewAmsterdam Pharma by 28.9% in the 1st quarter. HB Wealth Management LLC now owns 11,247 shares of the company's stock worth $230,000 after acquiring an additional 2,519 shares during the period. Hedge funds and other institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Stock Down 2.0%

Shares of NAMS traded down $0.48 during trading on Thursday, reaching $23.99. The company's stock had a trading volume of 306,104 shares, compared to its average volume of 869,619. The company has a fifty day moving average of $22.06 and a two-hundred day moving average of $20.30. NewAmsterdam Pharma Company N.V. has a twelve month low of $14.06 and a twelve month high of $27.29. The company has a market cap of $2.70 billion, a price-to-earnings ratio of -14.75 and a beta of -0.02.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.37. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.The company had revenue of $19.15 million for the quarter, compared to analyst estimates of $1.44 million. As a group, equities analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on NAMS. Cantor Fitzgerald began coverage on NewAmsterdam Pharma in a report on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 price target for the company. The Goldman Sachs Group began coverage on NewAmsterdam Pharma in a report on Thursday, July 17th. They issued a "neutral" rating and a $27.00 price target for the company. Wall Street Zen upgraded NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. Royal Bank Of Canada upped their price target on NewAmsterdam Pharma from $38.00 to $39.00 and gave the stock an "outperform" rating in a report on Thursday, August 7th. Finally, Stifel Nicolaus began coverage on NewAmsterdam Pharma in a report on Tuesday, June 10th. They issued a "buy" rating and a $44.00 price target for the company. Nine research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $41.55.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, Director James N. Topper bought 8,584 shares of the business's stock in a transaction on Monday, June 16th. The shares were bought at an average cost of $19.50 per share, with a total value of $167,388.00. Following the transaction, the director directly owned 3,022,153 shares in the company, valued at approximately $58,931,983.50. This trade represents a 0.28% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Douglas F. Kling sold 100,000 shares of the company's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $19.29, for a total value of $1,929,000.00. Following the sale, the chief operating officer directly owned 44,000 shares in the company, valued at approximately $848,760. This represents a 69.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders purchased 12,835 shares of company stock valued at $248,134 and sold 256,881 shares valued at $5,445,954. Corporate insiders own 20.84% of the company's stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.